|
|
 |
NEWS |

2011-12-13
Camurus enters exclusive collaboration, option and license agreement to its long acting octreotide product CAM2029 and the FluidCrystal® Injection depot technology
2011-12-13
Camurus tecknar exklusivt options- och licensavtal för det långtidsverkande peptidläkemedlet CAM2029, samt FluidCrystal® depåteknologi
2011-11-17
Camurus receives ISO 13485 certification
Go to newsarchive »
|
|